Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01300949 · ClinicalTrials.gov registry record · NA
Spaeth/Richman Contrast Sensitivity Test
A NA study, sponsored by Wills Eye.
- Completed
- Registry status
- NA
- Development phase
- 314
- Enrollment target
NCT01300949: Completed NA study, sponsored by Wills Eye.
NCT01300949 is a NA study that has completed, run by Wills Eye. The registered enrollment target is 314 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01300949, a NA study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- NA
- Development phase
- 314 participants
- Enrollment target
Study Summary
The Spaeth-Richman Contrast Sensitivity (SPARCS) test is a new method of assessing contrast sensitivity. The test, another way to measure vision, is performed on any standard computer with internet access. Patients will be tested with SPARCS and with the standard Pelli-Robson contrast test.
Primary Outcome
Contrast Sensitivity, a vision measurement, is performed with the Spaeth Richmond Contrast Sensitivity (SPARCS) test. This is a computerized measurement of vision in the central and peripheral fields using black and white stripes. Black stripes decrease in contrast becoming fainter and harder to see until they blend with the white background. Measurements are assessed in five areas of the visual field . Test results are reported for each area ranging from 0 to 20 (0 means can't see stripes; 20 m
Interventions
- DIAGNOSTIC_TEST Spaeth/Richman Contrast Sensitivity Test
- DIAGNOSTIC_TEST Pelli-Robson Contrast Sensitivity Chart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-04 |
| Phase | NA |
What the finished NCT01300949 record still lists
NCT01300949 is an interventional study that assigns participants to a tested intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Spaeth/Richman Contrast Sensitivity Test is the first listed.
NCT01300949 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01300949 about?
NCT01300949 is a clinical study titled "Spaeth/Richman Contrast Sensitivity Test". The Spaeth-Richman Contrast Sensitivity (SPARCS) test is a new method of assessing contrast sensitivity. The test, another way to measure vision, is performed on any standard computer with internet access. Patients will be tested with SPARCS and with the standard Pelli-Robson contrast test.
What is the current status of trial NCT01300949?
This trial is currently completed. It is a NA study. The enrollment target is 314 participants. The study started on 2010-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01300949?
The interventions under investigation include: Spaeth/Richman Contrast Sensitivity Test (DIAGNOSTIC_TEST), Pelli-Robson Contrast Sensitivity Chart (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01300949?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01300949's enrollment target sits among peer trials
314 323rd of 2000 higher than 1,678 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
- NCT06883097 · 314 participants · NA
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia